MergerAug 11, 2026, 08:12 AM
Theravance Biopharma to Merge with Zymeworks; Reports Q2 Loss
AI Summary
Theravance Biopharma, Inc. announced it entered into an Agreement and Plan of Merger with Zymeworks Inc. on June 28, 2026, under which it will become a wholly owned subsidiary of Zymeworks. Concurrently, the company reported a net loss of $5.9 million for the second quarter of 2026, a significant decline from the $54.8 million net income in the prior year, with diluted EPS falling to $(0.11). Total revenues for the quarter decreased to $20.7 million, and the company incurred $4.0 million in restructuring expenses and $6.1 million in transaction-related expenses, impacting its financial performance.
Key Highlights
- Entered into a Merger Agreement with Zymeworks Inc. on June 28, 2026.
- Reported a Q2 2026 net loss of $5.9 million, compared to net income of $54.8 million in Q2 2025.
- Diluted EPS for Q2 2026 was $(0.11), down from $1.08 in Q2 2025.
- Total revenues for Q2 2026 decreased to $20.7 million from $26.2 million in Q2 2025.
- Incurred $4.0 million in restructuring expenses and $6.1 million in transaction-related expenses in Q2 2026.
- Cash and cash equivalents increased to $219.8 million as of June 30, 2026, from $167.8 million at December 31, 2025.
- Total assets decreased to $469.8 million as of June 30, 2026, from $485.6 million at December 31, 2025.
Price Impact
More from TBPH